STOCK TITAN

ANI Pharmaceuticals Inc - ANIP STOCK NEWS

Welcome to our dedicated news page for ANI Pharmaceuticals (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on ANI Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANI Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANI Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
offering
-
Rhea-AI Summary
ANI Pharmaceuticals receives FDA approval for two generic drugs, Methsuximide Capsules and Alendronate Sodium Oral Solution, which have a combined annual market value of $6.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
fda approval
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
earnings
ANI Pharmaceuticals Inc

Nasdaq:ANIP

ANIP Rankings

ANIP Stock Data

1.47B
14.70M
10.1%
75.16%
1.18%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Baudette

About ANIP

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.